Vapreotide

Also known as: RC-160, Sanvar, Somatostatin Analog

A somatostatin analog used for GI bleeding and variceal hemorrhage.

Overview

Vapreotide is a synthetic octapeptide analog of somatostatin with longer duration of action. It is used primarily for acute esophageal variceal bleeding and has applications in various GI conditions where reduction of splanchnic blood flow is beneficial.

Mechanism of Action

Binds to somatostatin receptors, reducing splanchnic blood flow and portal pressure. Inhibits release of vasodilatory hormones (glucagon, VIP). Reduces GI secretions and motility.

Pharmacokinetics

Half-life approximately 30 minutes, much longer than native somatostatin. Continuous IV infusion or repeated SC dosing.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Variceal Bleeding

Dose

250 mcg bolus, then 250 mcg/hr

Frequency

Continuous infusion

Duration

Up to 5 days

Acute management

Research Areas

Variceal BleedingPortal HypertensionGI BleedingCarcinoid SyndromeAcromegaly

Key Research Findings

  • 1Effective for acute variceal bleeding
  • 2Reduces portal pressure
  • 3Longer acting than native somatostatin
  • 4Used in acute GI hemorrhage

Side Effects & Contraindications

Reported Side Effects

  • Hyperglycemia
  • Bradycardia
  • Nausea
  • Injection site pain

Contraindications

  • Hypersensitivity to somatostatin analogs

Safety Considerations

Monitor for hyperglycemia, bradycardia. May affect thyroid function with prolonged use.

Storage Requirements

Refrigerate 2-8C

Scientific References

Quick Reference

Sequence
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (cyclic)
Molecular Weight
1131 g/mol
Half-Life
~30 minutes
Bioavailability
Injectable
Research Stage
approved
Administration
IV infusion or SC